BioXcel Therapeutics Inc (NASDAQ: BTAI) on Friday, plunged -4.17% from the previous trading day, before settling in for the closing price of $2.64. Within the past 52 weeks, BTAI’s price has moved between $1.17 and $13.28.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 6.20%. The company achieved an average annual earnings per share of 79.24%. With a float of $18.88 million, this company’s outstanding shares have now reached $19.65 million.
BioXcel Therapeutics Inc (BTAI) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BioXcel Therapeutics Inc is 3.88%, while institutional ownership is 8.40%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -5.12 earnings per share (EPS) for the period topping the consensus outlook (set at -7.68) by 2.56. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 60.31% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
BioXcel Therapeutics Inc (BTAI) is currently performing well based on its current performance indicators. A quick ratio of 0.74 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.67, a number that is poised to hit -1.02 in the next quarter and is forecasted to reach -3.05 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Compared to the last year’s volume of 4.87 million, its volume of 1.14 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 20.78%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 19.68%, which indicates a significant increase from 8.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.22 in the past 14 days, which was lower than the 0.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.54, while its 200-day Moving Average is $3.00. Nevertheless, the first resistance level for the watch stands at $2.66 in the near term. At $2.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.88. If the price goes on to break the first support level at $2.44, it is likely to go to the next support level at $2.34. Now, if the price goes above the second support level, the third support stands at $2.22.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
Market capitalization of the company is 49.71 million based on 16,009K outstanding shares. Right now, sales total 2,270 K and income totals -59,600 K. The company made 120 K in profit during its latest quarter, and -19,190 K in sales during its previous quarter.
